TIRSEMA 44 is a compounded injectable solution that blends tirzepatide (40 mg) and semaglutide (4 mg) in a pre‑filled pen designed for subcutaneous injection. It is manufactured to high laboratory standards and intended for single‑patient use only.
This combo is generally used for:
Aggressive fat loss / appetite suppression
Improved insulin sensitivity
Reduced cravings & better satiety
Blood sugar control (off-label in many cases)
Key Benefits:
– Weight Management: Supports significant weight loss, with tirzepatide alone showing up to 22.5% body weight reduction over 72 weeks.
– Metabolic Support: Improves glycemic control and insulin sensitivity.
– Appetite Regulation: Reduces hunger and increases feelings of fullness.


